Cost comparison of post-remission strategies in younger and older AML patients in France-Reference-Cited by-同舟云学术

Cost comparison of post-remission strategies in younger and older AML patients in France

Published:2023-06-28 Issue:1 Volume:13 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Mounie Michael^ORCID,Dumas Pierre-Yves,Liva-Yonnet Sandra,Fabre Didier,Leguay Thibault,Galtier Jean,Berard Emilie,Hanta Ramaroson,Gilleron Véronique,Bertoli Sarah^ORCID,Pigneux Arnaud,Récher Christian,Costa Nadège

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

https://www.nature.com/articles/s41408-023-00874-y.pdf

Reference12 articles.

1. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994;331:896–903.

2. Löwenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood 2013;121:26–8.

3. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77.

4. Jaramillo S, Benner A, Krauter J, Martin H, Kindler T, Bentz M, et al. Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia. Blood Cancer J. 2017;7:e564.

5. Dumas PY, Bertoli S, Bérard E, Leguay T, Tavitian S, Galtier J, et al. Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome. Blood Adv. 2020;4:3840–9.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mini-consolidations or intermediate-dose cytarabine (IDAC) for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.;2024-06-10